IPCS 2026 kicks off tomorrow in Lugano
Institute of Oncology Research
Starting tomorrow, April 28–29, 2026, Lugano will host the International Prostate Cancer Symposium (IPCS), co-organized by the IOR Foundation and the APC Society. As prostate cancer care enters a new era of precision medicine, IPCS represents a key platform to explore and debate the most promising emerging therapies, paving the way for their transition from experimental strategies to future standards of care.
Under the leadership of Prof. Andrea Alimonti (IOR, Chair of IPCS), Prof. Jean-Philippe Theurillat (IOR, Co-Chair of IPCS) and Prof. Silke Gillessen (IOSI, Co-Chair of IPCS and Chair of APCCC), and supported by the American Association for Cancer Research (AACR) and the European Association of Urology (EAU), the symposium brings together in Lugano six hundred leading experts, researchers, clinicians, and industry representatives at the forefront of prostate cancer research.
Over two days of full immersion, IPCS discusses the latest developments in basic, translational, and clinical research, focusing on innovative therapeutic approaches, including next-generation androgen receptor inhibitors, combination therapies, theranostics, antibody-drug conjugates, and immunotherapy, to accelerate the translation of scientific advances into clinical practice.
The symposium will precede the Advanced Prostate Cancer Consensus Conference (APCCC) 2026, organized by the APC Society, which will take place in Lugano from April 30 to May 2, 2026. As one of the leading international meetings dedicated to advanced prostate cancer, APCCC will bring together over a thousand experts to define consensus recommendations that guide clinical practice worldwide.
The close succession of IPCS and APCCC creates a unique continuum between cutting-edge research and clinical decision-making, further reinforcing Ticino as a key hub for global oncology. This is a topic where a surge of cases is expected in the next years.
